Loading data for MDGL — first visit, this takes a few seconds.

알림

Madrigal Pharmaceuticals ... (MDGL)

NasdaqGS: MDGL · 실시간 가격 · USD

524.37

-0.50 (-0.10%)

종가 기준: Aug 19, 2026, 5:29 PM

-0.10% (1D)

데이터 없음

매수호가	511.93
시가총액	12.33B
매출 (ttm)	1.28B
순이익 (ttm)	-325.1M
베타	-1.00
EPS (ttm)	-14
P/E (ttm)	n/a
선행 P/E	55.43
P/B (ttm)	23.53
P/S (ttm)	9.60
Earnings Date	Nov 4, 2026

매도호가	512.55
거래량	287,368
평균 거래량 (20일)	364,191
시가	524.50
전일 종가	524.87
일중 범위	514.57 - 533.68
52주 범위	374.50 - 615.00
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

MDGL 소개

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania....

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Feb 6, 2007

직원 수 915

상장 거래소 NasdaqGS

티커 MDGL

웹사이트 https://www.madrigalpharma.com

전체 기업 정보

재무 실적

2025년 Madrigal Pharmaceuticals의 매출은 958.4M로, 전년 180.13M 대비 432.05% 증가했습니다. 순이익은 -288.28M로, -38.12% 감소했습니다.

재무제표

어닝 서프라이즈

Madrigal Pharmaceuticals가 Jul 30, 2026에 분기 실적을 발표했습니다:

매출 $364.25M 예상치 하회 $0, 및 71.17% 전년 대비 성장.

EPS -1.99 예상치 상회 0.24, 및 -4.74% 전년 대비 감소.

다음 실적 발표

Madrigal Pharmaceuticals Inc.의 실적 발표 예정일은 Nov 4, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

4일 전 · MarketBeat

Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands

Madrigal Pharmaceuticals (NASDAQ:MDGL) said Rezdiffra continued to post strong commercial growth in the second quarter of 2026, while the company expanded its development pipeline around the MASH ther...

2주 전 · The Fly

Walmart downgraded, Palantir upgraded: Wall Street's top analyst calls

2주 전 · 24/7 Wall St.

Here Are Tuesday’s Top Wall Street Analyst Research Calls: Apple, CoreWeave, eBay, Exxon Mobil, Intuit, Nebius Group, Palantir Technologies, SK hynix, and More

Wall Street wasted no time Monday, sending the Nasdaq surging past 25,900 while analysts took aim at some of the market's biggest names with fresh upgrades, downgrades, and new coverage that could res...

2주 전 · Simply Wall St.

Madrigal Pharmaceuticals (MDGL) Beat Earnings Estimates, Is It Still Below Fair Value?

Madrigal Pharmaceuticals (MDGL) drew attention after its second quarter 2026 earnings release, which highlighted Rezdiffra sales growth, stronger patient uptake, a smaller than expected quarterly loss...

2주 전 · Zacks

MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y Growth

Madrigal beats Q2 estimates as Rezdiffra sales lift revenues 71% year over year, but shares fall as investors weigh slower commercial growth.

2 페이지 중 1